Kodiak Sciences (NASDAQ:KOD) Reaches New 12-Month High on Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD) shares reached a new 52-week high during mid-day trading on Monday after Lifesci Capital raised their price target on the stock from $85.00 to $145.00. Lifesci Capital currently has an outperform rating on the stock. Kodiak Sciences traded as high as $64.57 and last traded at $64.57, with a volume of 4558251 shares traded. The stock had previously closed at $32.35.

KOD has been the topic of several other reports. JPMorgan Chase & Co. upped their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. HC Wainwright upped their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. UBS Group boosted their price objective on shares of Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research report on Monday. Finally, Wall Street Zen downgraded Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.43.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Positive Phase 3 DAYBREAK results: Zenkuda and tabirafusp-ted (KSI-501) met their primary endpoints in wet AMD, with efficacy reported as comparable to Regeneron’s established Eylea treatment. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• Positive Sentiment: Regulatory filing approaching: Kodiak plans to submit a biologics license application for Zenkuda, moving the drug closer to possible approval and revenue generation. The global retinal-drug market could exceed $32 billion by the end of the decade. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst support strengthened: UBS raised its price target to $120 and Lifesci Capital raised its target to $145, both maintaining bullish ratings. HC Wainwright also increased its target to $96 and assigned a buy rating.
• Neutral Sentiment: High volatility and valuation uncertainty: KOD has reached a new 52-week high after a dramatic rally, so further gains may depend on detailed trial data, regulatory progress and the eventual commercial profile of the drugs.
• Negative Sentiment: Options activity signals hedging or bearish speculation: Traders purchased 21,273 put options, approximately 1,361% above typical daily volume. This does not establish a fundamental problem, but it highlights elevated expectations and downside-risk concerns.

Hedge Funds Weigh In On Kodiak Sciences

A number of institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System raised its stake in shares of Kodiak Sciences by 6.9% during the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after purchasing an additional 554 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in Kodiak Sciences in the first quarter valued at approximately $26,000. Westfuller Advisors LLC bought a new stake in Kodiak Sciences in the first quarter worth approximately $26,000. EverSource Wealth Advisors LLC grew its position in Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of Kodiak Sciences during the 1st quarter worth $39,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

The company has a market cap of $5.73 billion, a price-to-earnings ratio of -21.75 and a beta of 2.18. The company’s 50 day moving average price is $40.26 and its 200 day moving average price is $38.27.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, equities research analysts forecast that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.